SCHEMBL20765124

SCHEMBL20765124

CC(C)(C)Oc1cc(OCc2ccccc2)cc(Cl)n1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX5 P09917 1/20 0.43
PRMT5 O14744 2/20 0.43
MAOB P27338 3/20 0.41
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
CYP3A4 P08684 1/20 0.40
PDGFRB P09619 1/20 0.39
PDGFRA P16234 1/20 0.39
CYP1A2 P05177 2/20 0.39
CYP1A1 P04798 1/20 0.39
CYP19A1 P11511 1/20 0.39
LMNA P02545 1/20 0.38
PTGS1 P23219 1/20 0.38
SLC6A2 P23975 1/20 0.38
CYP2C19 P33261 1/20 0.38
PTGS2 P35354 1/20 0.38
SLC6A3 Q01959 1/20 0.38
HIF1A Q16665 1/20 0.38
HDAC6 Q9UBN7 1/20 0.38
NPC1 O15118 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31627628 1.00 ALOX5 (0.43) ALOX5PRMT5MAOBMEN1KMT2A
SCHEMBL20776121 0.86 PRMT5 (0.39) ALOX5PRMT5MAOBMEN1KMT2A
SCHEMBL14744985 0.85 ALOX5 (0.50) ALOX5PRMT5MAOBMEN1KMT2A
SCHEMBL31287796 0.85 ALOX5 (0.50) ALOX5PRMT5MAOBMEN1KMT2A
SCHEMBL18864590 0.84 MAOB (0.51) ALOX5PRMT5MAOBMEN1KMT2A
SCHEMBL30522847 0.84 MAOB (0.51) ALOX5PRMT5MAOBMEN1KMT2A
SCHEMBL8550828 0.82 ALOX5 (0.56) ALOX5PRMT5MAOBMEN1KMT2A
SCHEMBL29666622 0.80 NUDT1 (0.48) ALOX5PRMT5MAOBMEN1KMT2A
SCHEMBL23531939 0.80 MAOB (0.50) ALOX5PRMT5MAOBMEN1KMT2A
SCHEMBL27718236 0.78 MEN1 (0.48) ALOX5MAOBMEN1KMT2APTGS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250236609-A1 VPS34 INHIBITORS AND METHODS OF USE THEREOF DECIPHERA PHARMACEUTICALS, LLC 2025-07-24 US disclosed
WO-2025129019-A1 VPS34 INHIBITORS AND METHODS OF USE THEREOF DECIPHERA PHARMACEUTICALS, LLC (US) 2025-06-19 WO disclosed
CN-116903526-A Pyridinylpyridinone compounds 思普瑞特生物科学公司 2023-10-20 CN disclosed
CN-116891431-A Pyridinylpyridinone compounds 思普瑞特生物科学公司 2023-10-17 CN disclosed
US-20230322772-A1 AZAINDOLYLPYRIDONE AND DIAZAINDOLYLPYRIDONE COMPOUNDS SPRINT BIOSCIENCE AB (SE) 2023-10-12 US disclosed
US-20230322772-A1 AZAINDOLYLPYRIDONE AND DIAZAINDOLYLPYRIDONE COMPOUNDS SPRINT BIOSCIENCE AB (SE) 2023-10-12 US disclosed
US-11780858-B2 Pyridinamine-pyridone and pyrimidinamine-pyridone compounds SPRINT BIOSCIENCE AB (SE) 2023-10-10 US disclosed
US-11780858-B2 Pyridinamine-pyridone and pyrimidinamine-pyridone compounds SPRINT BIOSCIENCE AB (SE) 2023-10-10 US disclosed
US-11780858-B2 Pyridinamine-pyridone and pyrimidinamine-pyridone compounds SPRINT BIOSCIENCE AB (SE) 2023-10-10 US disclosed
CN-116589462-A Azaindolylpyridone compounds and diazaindolylpyridone compounds 思普瑞特生物科学公司 2023-08-15 CN disclosed
EP-3672941-A1 PYRIDYLPYRIDONE COMPOUNDS Sprint Bioscience AB (SE) 2020-07-01 EP disclosed
EP-3672967-A1 AZAINDOLYLPYRIDONE AND DIAZAINDOLYLPYRIDONE COMPOUNDS Sprint Bioscience AB (SE) 2020-07-01 EP disclosed
CN-111247144-A Azaindolylpyridinone compounds and diazaindolylpyridinone compounds 思普瑞特生物科学公司 2020-06-05 CN disclosed
CN-111094244-A Pyridylpyridone compounds 思普瑞特生物科学公司 2020-05-01 CN disclosed
CN-111094271-A Pyridinamine-pyridinone compounds and pyrimidinamine-pyridinone compounds 思普瑞特生物科学公司 2020-05-01 CN disclosed
WO-2019038389-A1 PYRIDINAMINE-PYRIDONE AND PYRIMIDINAMINE-PYRIDONE COMPOUNDS SPRINT BIOSCIENCE AB (SE) 2019-02-28 WO disclosed
WO-2019038384-A1 AZAINDOLYLPYRIDONE AND DIAZAINDOLYLPYRIDONE COMPOUNDS SPRINT BIOSCIENCE AB (SE) 2019-02-28 WO disclosed
WO-2019038387-A1 PYRIDYLPYRIDONE COMPOUNDS SPRINT BIOSCIENCE AB (SE) 2019-02-28 WO disclosed
WO-2019038387-A1 PYRIDYLPYRIDONE COMPOUNDS SPRINT BIOSCIENCE AB (SE) 2019-02-28 WO disclosed
WO-2019038389-A1 PYRIDINAMINE-PYRIDONE AND PYRIMIDINAMINE-PYRIDONE COMPOUNDS SPRINT BIOSCIENCE AB (SE) 2019-02-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230322772-A1 AZAINDOLYLPYRIDONE AND DIAZAINDOLYLPYRIDONE COMPOUNDS AZI2, IAPP, ZFX ALOX5 2585/4885PRMT5 510/4885MAOB 1810/4885
US-11780858-B2 Pyridinamine-pyridone and pyrimidinamine-pyridone compounds PDXK, PLPBP, PNPO ALOX5 461/4885PRMT5 333/4885MAOB 190/4885
US-20250236609-A1 VPS34 INHIBITORS AND METHODS OF USE THEREOF VPS35, VPS28, VPS26B ALOX5 3101/4885PRMT5 2955/4885MAOB 3390/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.